Biochemical Pharmacology volume 80, issue 5, P674-682 2010 DOI: 10.1016/j.bcp.2010.03.011 View full text
|
|
Share
Maria Russo, Annalisa Mupo, Carmela Spagnuolo, Gian Luigi Russo

Abstract: A recent and innovative strategy in cancer therapy is the activation of apoptosis in tumour cells specifically expressing death receptors (DR) belonging to the tumour necrosis factor (TNF) receptor superfamily and including several members known since the early '90. Among these, those largely studied for clinical purpose are TNF, CD95, and TRAIL receptors. Promising results are expecting from ongoing phases I/II clinical trials proving the therapeutic efficacy of DR agonistic antibodies and/or recombinant prot…

expand abstract